Advertisement

Clinical Strategies for Developing Next-Generation Cancer Precision Medicines

  • Chee Gee SeeEmail author
Chapter

Abstract

The clinical development of EGFR inhibitors for non-small cell lung cancer is one of the greatest examples of precision medicine. The three generations of different EGFR inhibitors highlight the growing knowledge and implementation of genetic information into clinical thinking and hypotheses, the testing of these hypotheses in clinical development and, ultimately the acceptance of such targeted therapy as valuable transformational clinical tools. As each generational EGFR-inhibitor therapy is tested in the clinic, the responses of patients together with their individual genomic information provides the stage for the next-generational clinical development of this class of drugs. Non-small cell lung cancer behaves classically like most cancers, and in due time, responding patients will inevitably develop resistance to the targeted therapy. Using a broad range of disease biology, genetic dissection and clever chemistry, the generational clinical development of EGFR inhibitors for non-small cell lung cancer is one of the most inspiring and motivational accounts of how precision medicine is transforming healthcare worldwide.

Keywords

Precision medicine Lung cancer Mutation screening Personalized medicine Drug target Clinical trials 

References

  1. Castellanos EH, Horn L (2015) Generations of epidermal growth factor receptor tyrosine kinase inhibitors: perils and progress. Curr Treat Options in Oncol 16:51CrossRefGoogle Scholar
  2. Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC, Lee CK (2017) Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer. J Thorac Oncol 12(4):633–643CrossRefGoogle Scholar
  3. Douillard J, Hirsch V, Mok TS et al (2008) Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol 26(suppl):8001CrossRefGoogle Scholar
  4. Dungo RT, Keating GM (2013) Afatinib: first global approval. Drugs 73:1503–1515CrossRefGoogle Scholar
  5. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237–2246CrossRefGoogle Scholar
  6. Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong S-S, Sriuranpong V et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874CrossRefGoogle Scholar
  7. Grandis JR, Sok JC (2004) Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102:37–46CrossRefGoogle Scholar
  8. Gray J, Haura E (2014) Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res 3:360–362PubMedPubMedCentralGoogle Scholar
  9. Hirsch FR, Varella-Garcia M, Cappuzzo F (2009) Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28:S32–S37CrossRefGoogle Scholar
  10. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, Suehisa H, Ouchida M, Aoe K, Aoe M, Kiura K, Shimizu N, Date H (2006) Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66(16):7854–7858CrossRefGoogle Scholar
  11. Kazandjian D, Blumenthal GM, Yuan WS, He K, Keegan P, Pazdur R (2016) FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation–positive non–small cell lung cancer. Clin Cancer Res 22:1307–1312CrossRefGoogle Scholar
  12. Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809–1818CrossRefGoogle Scholar
  13. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792CrossRefGoogle Scholar
  14. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158CrossRefGoogle Scholar
  15. Lemmon MA, Schlessinger J (2010) Cell signalling by receptor tyrosine kinases. Cell 141:1117–1134CrossRefGoogle Scholar
  16. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefGoogle Scholar
  17. Merrick D, Kittelson J, Wintherhalder R, Kotantoulos G, Ingeberg S, Keith RL et al (2006) Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res 12:2281–2288CrossRefGoogle Scholar
  18. Mok TS et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957CrossRefGoogle Scholar
  19. Mok TS et al (2017) Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med 376:629–640CrossRefGoogle Scholar
  20. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500CrossRefGoogle Scholar
  21. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760–774CrossRefGoogle Scholar
  22. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306–13311CrossRefGoogle Scholar
  23. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73CrossRefGoogle Scholar
  24. Pérez-Soler R (2004a) Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 6(Suppl 1):S20–S23CrossRefGoogle Scholar
  25. Pérez-Soler R (2004b) The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 10:4238s–4240sCrossRefGoogle Scholar
  26. Pérez-Soler R, Chachoua A, Hammond LA et al (2004) Determinants of tumor response and survival with erlotinib in patients with non—small-cell lung cancer. J Clin Oncol 22:3238–3247CrossRefGoogle Scholar
  27. Posner I, Engel M, Gazit A, Levitzki A (1994) Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol Pharmacol 45:673–683PubMedGoogle Scholar
  28. Reck M et al (2010) Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment Study. J Thorac Oncol 5:1616–1622CrossRefGoogle Scholar
  29. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232CrossRefGoogle Scholar
  30. Sznol M (2010) Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype? Curr Opin Investig Drugs 11:1340PubMedGoogle Scholar
  31. Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K et al (2013) Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 3:1404–1415CrossRefGoogle Scholar
  32. Wang S, Song Y, Yan F, Liu D (2016) Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. Front Med 10(4):383–388CrossRefGoogle Scholar
  33. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M et al (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070–1074CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Life Science Expert at PA Consulting LtdLondonUK
  2. 2.CGS Precision Medicine ConsultancyLetchworth Garden CityUK

Personalised recommendations